ByrneWallace advises on trade sale of Stokes Bio to NASDAQ quoted Life Technologies

Tuesday, 4 May 2010

ByrneWallace advised the shareholders of Stokes Bio on the sale of their shareholdings in Stokes Bio Limited as part of a trade sale of the company to NASDAQ quoted Life Technologies. The sale of Stokes Bio for USD$44m represents a significant success for the Irish life sciences sector.  We wish the management and new owners every continued success in the future. For further information please contact Colin Sainsbury or Dennis Agnew who advised the shareholders on this major transaction.

ByrneWallace is Ireland’s leading life sciences practice.  Last year we advised Stokes Bio on a major international licensing and R&D collaboration agreement with Monsanto, a global agricultural and biotechnology company.

• What we do
• Who to contact
• Subscribe to our publications